merged_alzheimers-blood-test.txt
<question_number>1</question_number>
<answer>Experts caution against using the blood test for cognitively healthy individuals because there are no therapies to offer if Alzheimer's pathology is detected without cognitive impairment, and it may cause anxiety and other psychological reactions.</answer>
<question_number>2</question_number>
<answer>The blood test was wrong only about 10 percent of the time, while primary care doctors were wrong 41 percent of the time when they believed patients did not have Alzheimer's.</answer>
<question_number>3</question_number>
<answer>The blood test's accuracy is lower in patients with subjective cognitive decline because many people with this condition do not actually have Alzheimer's.</answer>
<question_number>4</question_number>
<answer>The remaining hurdle is for blood test analysis to be easily integrated into hospital laboratory systems rather than requiring outside labs.</answer>
<question_number>5</question_number>
<answer>The protein measured was a form of tau called ptau-217, which provided the most precise assessment of Alzheimer's pathology compared to other blood tests.</answer>
<question_number>6</question_number>
<answer>Dr. Boxer suggested that blood tests for Alzheimer's should be used only in the context of a research study, given the current lack of preventative treatments.</answer>
<question_number>7</question_number>
<answer>Kidney disease can cause elevated ptau-217 levels not associated with Alzheimer's.</answer>
<question_number>8</question_number>
<answer>Experts are concerned that using blood tests for cognitively healthy individuals to predict future Alzheimer's development could lead to anxiety and other psychological reactions due to the lack of available therapies.</answer>
<question_number>9</question_number>
<answer>Primary care doctors were incorrect 41 percent of the time when they thought patients did not have Alzheimer's.</answer>
<question_number>10</question_number>
<answer>The potential benefit is increased access to screening for people from racial and ethnic minorities and low-income and rural communities.</answer>